[A multi-institutional study on the efficacy and toxicity of imipenem/cilastatin sodium in severe infections complicating hematological diseases and cancers in children. Study Group of Infectious Diseases in Pediatric Hematology/Oncology in Hokkaido].
A multi-institutional study was conducted between September 1990 and April 1992 to evaluate the efficacy and toxicity of imipenem/cilastatin sodium (IPM/CS) in severe infections in cases of granulocytopenia in children with hematological diseases and cancers. A total of 60 episodes of infection were treated with the drug, and an overall efficacy rate of 80% (48/60) was obtained. The efficacy rate in patients who were positive for Endospecy test was 90.0%. A group of patients who had previously received other antibiotics showed an efficacy rate of 79.2%, while the patients who had not received previous antibiotic treatment showed an efficacy rate of 80.6%. The difference between the 2 groups was statistically insignificant, however. Granulocyte counts appeared to have influence on the efficacy of the drug, but the influence was not strong. Three patients had nausea, vomiting and/or diarrhea, and 2 other patients showed abnormal liver function test parameters though they recovered soon after the cessation of the drug treatment. From these results, we have concluded that IPM/CS is an effective antibiotic for treatment of severe infections with hematological diseases and cancers in children.
Takeda
T
T
Department of Pediatrics, Sapporo National Hospital.
Hatae
Y
Y
Nakadate
H
H
Fujita
K
K
Suzuki
Y
Y
Wagatsuma
Y
Y
Kon-No
M
M
Takase
A
A
Takahashi
Y
Y
Nagashima
T
T
D000293:Adolescent; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D015377:Cilastatin / Q000008:administration & dosage; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage; D007223:Infant; D007938:Leukemia / Q000150:complications*; D007970:Leukopenia / Q000150:complications; D008297:Male; D009369:Neoplasms / Q000150:complications*; D011014:Pneumonia / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy
D015377:Cilastatin; D015378:Imipenem